Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > New Chemical Entities, Drug Leads

Categories

[Search within category]

A New Class of mTOR Inhibitors for Targeted Treatment of Anti-cancer, Anti-aging, and Anti-autism and Regenerative Medicine

Novel hybrid inhibitors of mTOR (mammalian target of rapamycin kinase) that selectively target mTORC1 (mammalian target of rapamycin complex 1) and completely inhibit downstream phosphorylation of its substrates for cancer treatment as well as regenerative medicine, aging and autism (TSC mutations).

Preganancy Hormone-Containing Combination Products for the Continuous Treatment of Autoimmune Diseases

UCLA researchers in the Departments of Neurology have discovered that the combination of certain pregnancy hormones can treat autoimmune disorders like multiple sclerosis.

Chemically Modified Nell-1 and Methods of Making and Using the Same

UCLA researchers have developed ways to chemically modify NELL-1, an osteoinductive factor, that significantly prolong the in vivo circulation time of the protein and retain its osteoblastic activity without any appreciable cytotoxicity.

Use of ApoA-1 to Treat and Prevent Pro-Inflammatory Conditions

UCLA researchers in the Department of Obstetrics and Gynecology have discovered that ApoA-I can be used to treat and prevent pro-inflammatory skin conditions.

Small Molecules for Melanoma Treatment

Traditional anti-cancer treatments used for metastatic melanoma (skin cancer) can result in cell toxicity, poor efficacy, and low patient survival. UCI researchers have uncovered a class of potent compounds that inhibit cancer cell growth and induce cancer cell death by targeting RhoJ signaling pathways.

Anti-Oxidant Response Modifiers as Treatment for HIV-Associated Neurocognitive Disorder

UCLA researchers have identified anti-oxidative response modulators as a potential treatment for HIV-associated neurocognitive disorders (HAND).

Antiviral Compounds for HIV and Other Viral Infections

This invention identifies a novel class of HIV inhibitors targeting RNA-protein interactions.

Antibodies for Pseudomonas (P.) aeruginosa

Researchers at the University of California, Davis have developed recombinant antibodies (VHH or nanobodies) to diagnose and treat Pseudomonas (P.) aeruginosa infection.

Novel Inhibitors of Mitochondrial Electron Transport

Researchers at the University of California, Davis have discovered a class of compounds that both bind to a unique newly-discovered binding site in respiratory complex III and act as inhibitors of electron transport for use as mitochondrial anti-cancer drugs.

Anti-Androgens for the Treatment of Chemotherapy Resistant Prostate Cancers

Researchers at the University of California, Davis have discovered a special class of androgen inhibitors for the treatment of chemotherapeutic prostate resistant cancers.

Lipid(S) Conjugated Anticancer Smac Derivatives

UCLA researchers in the Department of Medicine have synthesized monomeric and dimeric second mitochondria derived activator of caspases (SMAC) analogs that can be used for anticancer therapeutics.

Compound Library Made Through Phosphine-Catalyzed Annulation/Tebbe/Diels-Alder Reaction

UCLA researchers in the Department of Chemistry and Biochemistry have developed a small molecule library consisting of a large variety stereochemical variants.

PAC1 Receptor Agonists for Treatment of Obesity, Diabetes, and Fatty Liver Disease

UCLA researchers have developed novel PAC1 receptor agonists (MAXCAPs) that specifically bind and activate PAC1 receptors to induce satiety and treat multiple metabolic diseases.

Apoe4-Targeted Theraputics That Increase Sirt1

UCLA researchers have identified Alaproclate (A03) as a promising drug candidate to treat Mild Cognition Impairment (MCI) and Alzheimer’s disease (AD) through inhibition of the ApoE4 neurotoxicity.

DEPTOR Inhibitors

Researchers at UCLA have found a small molecule that prevents the binding of DEPTOR to mTOR. The inhibition of interaction between DEPTOR and mTOR results in selective death of multiple myeloma cells, and can therefore be used as a targeted therapy for the disease.

A Novel ER Beta Ligand Prodrug to Treat MS and Other Neurodegenerative Diseases

Researchers from the Department of Neurology and the Department of Chemistry and Biochemistry at UCLA have developed a novel ERβ ligand prodrug that is structurally designed to more easily cross the blood-brain barrier for treatment of multiple sclerosis.

Inhibitors Of The N-Terminal Domain Of The Androgen Receptor

UCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.

A Novel Method to Generate Specific and Permanent Macromolecular Covalent Inhibitors

UCSF researchers have invented a novel method to generate covalent macromolecular inhibitors. This strategy allows a peptide inhibitor to bind to its target protein specifically and irreversibly through proximity-enabled bioreactivity.

Protein Kinase C Epsilon Small Molecule Inhibitors to Treat Pain, Anxiety, Alcoholism, and Nicotine Addiction

This invention provides new inhibitors to protein kinase C epsilon (PKCε) for the treatment and prophylaxis of various diseases such as pain, anxiety, alcoholism, inflammation, cancer, diabetes, and other conditions.

Antisense Oligonucleotides and Drug Conjugates for Obesity and Diabetes Treatment

The obesity epidemic is an ongoing issue leading to significant economic and social burden, in part due to its role in the development of diabetes. Only three DFA-approved drugs for obesity treatment currently exist, none of which are without significant side effects and risks. Researchers at UCI have developed a DNA-based approach that activates metabolism, to target genes only in the fat and liver, causing increased energy expenditure and weight loss without affecting other organs. These present a viable approach to obesity treatment with minimal side effects in comparison to current drug treatments.

Methods for purifying and treating wounds with a proprietary biological agent, and to coat biomaterials designed to be synthetic substrates, aimed at promoting healing.

This invention describes methods for using a proprietary biological agent to improve the quality and speed of wound healing, and for coating a biomaterial to serve as an artificial epithelium for severe wounds. Also described are methods to produce high yields of the biological agent and of its purification.

Novel Antiviral Compounds to Treat Enterovirus Infections

Researchers in UCLA Department of Molecular & Medical Pharmacology have used a rapid, live virus assay to develop potent enterovirus inhibitors.

Compositions for Enhancing Beta Cell Maturation, Health, and Function

Beta cell failure is the central cause of type-2 diabetes. Researchers at UCI have developed molecules for treating diabetes that target proteins on the surface of beta cells and induce their clustering. This clustering results in an increase in insulin secretion and content and promotion of beta cell maturation. Furthermore, the clustering effect seen with these compositions may promote both proliferation and the reversal of de-differentiation.

PharmaCoLogic: Preclinical Cardiac Drug Screening

Researchers at the University of California, Davis have developed PharmaCoLogic: a computer based preclinical screening model to predict the effects of developmental drugs and drug induced cardiotoxicity.

Treatment To Prevent Post-Antibiotic Expansion Of Enterobacteriaceae

Researchers at the University of California, Davis have identified a nuclear receptor as a new target for treatments preventing post-antibiotic Enterobacteriaceae expansion.

  • Go to Page: